A comparative randomized, open-label, rater-blinded study of paliperidone palmitate and risperidone long-acting injectable therapy in patients with schizophrenia

被引：0
|
作者：
Li, H. [1 ]
Rui, Q.
Ning, X.
Xu, H.
Gu, N. [1 ]
机构：
[1] Shanghai Mental Hlth Ctr, Shanghai, Peoples R China
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2010年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：167 / 167
页数：1
相关论文
共 50 条
  • [21] COST EFFECTIVENESS OF PALIPERIDONE PALMITATE VERSUS RISPERIDONE LONG-ACTING INJECTABLE, QUETIAPINE AND OLANZAPINE FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA IN COLOMBIA
    Casallas, C.
    Ariza, J. G.
    VALUE IN HEALTH, 2013, 16 (07) : A695 - A695
  • [22] Evaluation of paliperidone palmitate long-acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia
    Brown, Brianne
    Turkoz, Ibrahim
    Mancevski, Branislav
    Mathews, Maju
    EARLY INTERVENTION IN PSYCHIATRY, 2020, 14 (04) : 428 - 438
  • [23] Effectiveness of Switching From Long-Acting Injectable Fluphenazine or Haloperidol Decanoate to Long-Acting Injectable Risperidone Microspheres: An Open-Label, Randomized Controlled Trial
    Covell, Nancy H.
    McEvoy, Joseph P.
    Schooler, Nina R.
    Stroup, T. Scott
    Jackson, Carlos T.
    Rojas, Ingrid A.
    Essock, Susan M.
    JOURNAL OF CLINICAL PSYCHIATRY, 2012, 73 (05) : 669 - 675
  • [24] EFFICACY OF LONG-ACTING INJECTABLE RISPERIDONE IN DELUSIONAL DISORDER: AN OPEN-LABEL, NATURALISTIC AND PROSPECTIVE STUDY
    Gonzalez Rodriguez, A.
    Molina Andreu, O.
    Imaz Gurrutxaga, M. L.
    Pons Villanueva, A.
    EUROPEAN PSYCHIATRY, 2012, 27
  • [25] Cost minimization analysis comparing paliperidone palmitate with risperidone long-acting injectable in Spain
    Quintero, I.
    Gonzalez, B.
    Garcia, I.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 50 - 50
  • [26] Long-acting injectable risperidone in treatment refractory patients: A 14-week open-label pilot study
    Procyshyn, Ric M.
    Barr, Alasdair M.
    Flynn, Sean
    Schenk, Chris
    Ganesan, Soma
    Honer, William G.
    SCHIZOPHRENIA RESEARCH, 2010, 123 (2-3) : 273 - 275
  • [27] Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia
    Alphs, Larry
    Bossie, Cynthia A.
    Fu, Dong-Jing
    Ma, Yi-Wen
    Sliwa, Jennifer Kern
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (07) : 1029 - 1042
  • [28] Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder - Randomised, controlled, open-label study
    Keks, Nicholas A.
    Ingham, Michael
    Khan, Akbar
    Karcher, Keith
    BRITISH JOURNAL OF PSYCHIATRY, 2007, 191 : 131 - 139
  • [29] Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders
    Parellada, Eduard
    Kouniakis, Filippos
    Siurkute, Aldona
    Schreiner, Andreas
    Don, Liana
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2010, 25 (03) : 149 - 154
  • [30] Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate
    Joshi, Kruti
    Pan, Xiaoyun
    Wang, Rosa
    Yang, Erru
    Benson, Carmela
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (11) : 1873 - 1881
12345